Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer

Molecular Urology

Volumn 4, Issue 3, 2000, Pages

  D'Amico, A V ^a   Tomaszewski, J E ^a   Renshaw, A A ^a   Wein, A ^a   Richie, J P ^a   Grignon, D ^a   Zietman, A ^a   Bostwick, D ^a   Whittington, R ^a   Malkowicz, S B ^a   Schultz, D ^a   Silver, B ^a   Henry, L ^a   Hurwltz, M ^a   Kaplan, I ^a   Beard, C J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONFERENCE PAPER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SCORING SYSTEM;

BIOPSY; COHORT STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033762181     PISSN: 10915362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update
2. PSA failure despite pathologic organ confined disease: The basis for an adjuvant therapy trial
3. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy
4. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy
5. Equivalent bio-chemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml
6. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
7. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
8. Histologic grading and staging of prostatic carcinoma
9. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios
10. For the American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy
11. Prostate specific antigen and radiation therapy for clinically localized prostate cancer
12. A Multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer
13. Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate specific antigen driven outcome analysis
14. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer
15. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome
16. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation
17. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy
18. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome
19. Outcome based staging for clinically localized adenocarcinoma of the prostate
20. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
21. Prostate specific antigen based disease control following ultrasound guided I 125 implantation for stage T1/T2 prostatic carcinoma
22. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
23. Non-parametric estimation from incomplete observations
24. Radical perineal prostatectomy: Oncological outcome during a 20-year period
25. Natural history of progression after PSA elevation following radical prostatectomy